Research programme: gene therapeutics - Kadmon Gene Therapy Holdings
Latest Information Update: 17 Jun 2015
At a glance
- Originator Kadmon Corporation
- Class Gene therapies
- Mechanism of Action Gene transference
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Blindness
Most Recent Events
- 01 May 2015 Preclinical trials in Blindness in USA (unspecified route) prior to May 2015